COCH icon

Envoy Medical

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
Newsfile Corp
11 days ago
Envoy Medical Regains Compliance with Nasdaq Listing Requirement
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b). As previously disclosed, the Company received a notice from Nasdaq on February 25, 2025, indicating that it was not in compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities (MVLS) of $35 million.
Envoy Medical Regains Compliance with Nasdaq Listing Requirement
Neutral
Newsfile Corp
12 days ago
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry. "We believe the future of the cochlear implant industry is fully implanted devices and that our approach is novel when compared to other designs," said Brent Lucas, Chief Executive Officer of Envoy Medical.
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
Neutral
Newsfile Corp
16 days ago
Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial
Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor Closing of $30 million in gross proceeds in upsized offering, with up to an additional $48 Million upon exercise of milestone warrants, provides potential funding through commercialization Company hosting Fireside Chat with Dr. Theodore McRackan, on February 25 th at 10 a.m. ET, to discuss his initial experiences as clinical trial's leading implanter White Bear Lake, Minnesota--(Newsfile Corp. - February 19, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today provided a business update highlighting its recent transformative financing led by long-term institutional investors and existing shareholders, noting further positive clinical trial progress, and announcing an upcoming fireside chat.
Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial
Neutral
Newsfile Corp
18 days ago
Envoy Medical Nears Completion of Enrollment in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant
45 of 56 Patients Implanted; Enrollment Completion Anticipated by End of March White Bear Lake, Minnesota--(Newsfile Corp. - February 17, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced continued progress in enrollment for its pivotal clinical trial of the investigational fully implanted Acclaim® cochlear implant. To date, 45 patients have been successfully implanted and are officially enrolled in the study.
Envoy Medical Nears Completion of Enrollment in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant
Neutral
Newsfile Corp
22 days ago
Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering
$30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cash Offering led by Nantahala Capital, with participation of healthcare-dedicated funds, including Broadfin Holdings, and participation from existing shareholder, Glen Taylor, and members of the Company's board of directors and management Net proceeds extend anticipated cash runway into second half of 2027, beyond expected PMA submission; if milestone-linked warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond first full year of commercialization White Bear Lake, Minnesota--(Newsfile Corp. - February 12, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the closing of its previously announced upsized public offering of an aggregate of 75,000,000 shares of its Class A common stock (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 45,000,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) and Series A-2 common warrants to purchase up to 75,000,000 shares of Class A common stock (or pre-funded warrants in lieu thereof), at a combined public offering price of $0.40 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants. "We are pleased to have closed this transformational financing anchored by Nantahala Capital and with strong support from Glen Taylor, other healthcare funds, and several members of the Board of Directors and management.
Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering
Neutral
GlobeNewsWire
1 month ago
Envoy Medical to Present at the Small Cap Growth Virtual Investor Conference February 5
WHITE BEAR LAKE, Minn., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health company pioneering fully implanted hearing solutions, today announced that management will participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026.
Envoy Medical to Present at the Small Cap Growth Virtual Investor Conference February 5
Neutral
Newsfile Corp
2 months ago
Envoy Medical Reaches Enrollment Milestone in Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
Enrollment momentum accelerates as Company advances toward full enrollment White Bear Lake, Minnesota--(Newsfile Corp. - December 18, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that its pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant has achieved yet another milestone by reaching the midway point of the study's full enrollment target. Despite holiday scheduling and year-end operating room constraints, enrollment is progressing at a steady pace.
Envoy Medical Reaches Enrollment Milestone in Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
Neutral
Newsfile Corp
2 months ago
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
Momentum continues to build for Company as series of clinical milestones are met, design choices cement differentiation from competition, and timeline comes into focus White Bear Lake, Minnesota--(Newsfile Corp. - December 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the completion of the first set of activations in the final stage of the pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant. These activations were performed at Shohet Ear Associates in Seal Beach, California and the Center for Neurosciences Ear and Hearing Center in Tucson, Arizona, two of the seven investigational sites involved in the study.
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
Neutral
Newsfile Corp
3 months ago
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
Event to Take Place December 11th at 4:30 P.M. ET White Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:30 P.M.
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
Positive
Zacks Investment Research
3 months ago
Envoy Medical, Inc. (COCH) Upgraded to Buy: Here's Why
Envoy Medical, Inc. (COCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Envoy Medical, Inc. (COCH) Upgraded to Buy: Here's Why